Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- MSD Aims to Become Top-3 Company in Japan
October 11, 2010
- Nitto Denko to Develop siRNA Drugs in the US
October 11, 2010
- Eisai Licenses Ravuconazole Prodrug to Brain Factory
October 11, 2010
- Japan, South Korea, China to Jointly Study Ethnic Differences
October 11, 2010
- Nippon Shinyaku Licenses Prulifloxacin to Algorithm
October 11, 2010
- Takeda to Set Up Subsidiary in India
October 11, 2010
- JPMA President Hasegawa Calls For Enhancement of R&D Tax Break System
October 11, 2010
- DSP Obtains Option Right for SB623 from SanBio
October 11, 2010
- JGC Takes Over CROBusiness from Tokyo CRO
October 11, 2010
- EML4-ALK Mutations Seen in 5.2% of Japanese Lung Cancer Patients
October 11, 2010
- Nippon Kayaku's NK105 Found Effective for Stomach Cancer in PII
October 11, 2010
- Mr Shimada to Take the Helm of Taiyo
October 11, 2010
- Avastin Established as Standard Therapy for Lung Cancer in Japan
October 11, 2010
- Japan Participates in Multinational PIII Trial of Vadimezan
October 11, 2010
- Kyokaikenpo to Beef Up Measures to Promote Use of Generics
October 11, 2010
- Study Results on Avastin Biomarkers Expected Soon in Stomach Cancer
October 11, 2010
- Data at Week 24 of Treatment with Taspoglutide Presented at EASD
October 11, 2010
- Anti-Flu Virus Drug Inavir Included in NHI Price List
October 11, 2010
- Dr Boku Expresses Hope for Everolimus in 2nd-Line Therapy for Stomach Cancer
October 11, 2010
- Approval of Takepron for Prevention of NSAID-Induced Ulcers Welcome: Prof. Soen
October 11, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…